MedTrace Logo

Cognitive Evolution in Tysabri Treated Multiple Sclerosis Patients - A Three Year Extension

NCT02383550 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 46

Last updated 2017-11-06

No results posted yet for this study

Summary

This study is designed to demonstrate that Tysabri is effective in maintaining cognition in MS patients after 5 or more years of continuous treatment.

During a second period of 36 months, the extension study will assess the evolution of cognitive function in Tysabri treated MS patients using the Symbol Digit Modalities Test (SDMT) and a CogState battery of tests.

Conditions

Interventions

OTHER

Observational Cognitive assessments

Observational

Sponsors & Collaborators

  • CogState Ltd.

    collaborator INDUSTRY

  • Clinique Neuro-Outaouais

    lead OTHER

Principal Investigators

  • Francois Jacques, MD · Clinique Neuro-Outaouais

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-12-31
Primary Completion
2017-08-30
Completion
2017-08-30

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02383550 on ClinicalTrials.gov